Used in cancer immunotherapy to block the CD47 protein on tumor cells, which helps cancer evade the immune system. By inhibiting CD47, the antibody enables macrophages and other immune cells to recognize and destroy cancer cells more effectively. Investigated in clinical trials for hematologic malignancies such as lymphoma and leukemia, as well as solid tumors. Often studied in combination with other antibodies like rituximab to enhance tumor cell phagocytosis. Also explored for its role in improving antigen presentation and activating broader anti-tumor immune responses.